Myasthenia Gravis

A one dollar bill sitting next to a declining stock graph
Favicon Fierce Pharma

Vor Bio's surprise $4B revival deal splits investor reactions

In response to the deal, Vor's stock price more than doubled in premarket trading, while RemeGen’s stock price in Hong Kong dropped 18% Thursday.
Angus Liu Jun 26, 2025 10:55am
A photo finish at a horse race with both horses crossing the finish line

J&J links FcRn blocker to sustained benefits as FDA ruling nears

Apr 8, 2025 10:21am
relay

Immunovant posts phase 3 autoimmune win but won't seek approval

Mar 19, 2025 9:15am
JNJ

J&J posts adolescent myasthenia gravis data on $6B FcRn blocker

Oct 15, 2024 9:25am
FDA

J&J files for FDA approval of $6.5B autoimmune drug

Aug 29, 2024 8:57am
data

Cartesian claims autoimmune CAR-T win after changing endpoint

Jul 2, 2024 7:56am